A phase I study combining the HDAC inhibitor vorinostat with capecitabine and radiotherapy in patients with localized pancreatic ductal adenocarcinoma (PDAC) was well tolerated, resulting in four R0 resections among 11 patients who underwent surgical exploration and a median overall survival (OS) of 1.1 years (NCT00983268) [28]. The gene discussed is HDAC9; the disease is pancreatic ductal adenocarcinoma.